ÂÜÀòÂÒÂ×

Dr. Karabelas is a Partner at Care Capital, LLC, a life sciences venture firm. He is also a member of the board of RegenXbio, a publicly traded gene therapy company; a member of the board of Bausch Health Companies, Inc., a public company; and a member of the board of Braeburn Pharmaceuticals, a privately held company focusing on treatments for addiction and pain. Dr. Karabelas is also a member of the Strategic Advisory Board of Broadview Ventures.

Previous to these positions, Dr. Karabelas founded the Novartis Bio Venture Fund; was the CEO of Worldwide Pharmaceuticals, Head of all Healthcare Businesses and member of the Executive Committee at Novartis, AG; was Executive Vice President of Pharmaceuticals at SmithKline Beecham, Chairman of the Pharmaceutical Executive and Development Committees, and a member of the Executive Committee of SmithKline Beecham. Previous to these senior executive positions, Dr. Karabelas had a typically progressive career in pharmaceutical sales and marketing at SmithKline and French. He was also a Professor of Pharmacokinetics.

Dr. Karabelas has founded several companies: CytoTherapeutics, Inc., Vanda Pharmaceuticals Inc., and Minerva Pharmaceuticals. He is former Chairman of Human Genome Sciences, Vanda Pharmaceuticals Inc., Renovo, NitroMed, Inc., and SkyePharma plc.

Dr. Karabelas holds a Ph.D. in Pharmaceutical Sciences and Pharmacokinetics from the Massachusetts College of Pharmacy and a Bachelor of Sciences in BioChemistry from the University of New Hampshire.